References
- International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation, 2015
- Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014
- Wong ND, Patao C, Wong K, et al. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res 2013;10:505-13
- American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care 2017;40(Suppl. 1):S1-S131
- Turner LW, Nartey D, Stafford RS, et al. Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 2014;37:985-92
- Brodovicz KG, Kou TD, Alexander CM, et al. Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database. Int J Clin Pract 2013;67:449-54
- Zhang Q, Rajagopalan S, Mavros P, et al. Baseline characteristic differences between patients prescribed sitagliptin vs. other antihyperglycemic agents: analysis of a US electronic medical record database. Curr Med Res Opin 2010;26:1697-703
- Cai B, Katz L, Alexander CM, et al. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. Int J Clin Pract 2010;64:1601-8
- Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54
- Grabner M, Peng X, Geremakis C, Bae J. Demographic and clinical profiles of type 2 diabetes mellitus patients initiating canagliflozin versus DPP-4 inhibitors in a large U.S. managed care population. J Manag Care Spec Pharm 2015;21:1204-12
- Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
- Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
- Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
- American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009;32(Suppl 1):S13-S61